Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SKR
|
|||
| Former ID |
DAP000231
|
|||
| Drug Name |
Clonidine
|
|||
| Synonyms |
clonidine; Clonidin; Duraclon; Chlornidinum; 4205-90-7; Catapres-TTS; Catarpresan; Catarpres; Adesipress; Catapres; Catapressan; Catapresan; ST 155BS; ST-155-BS; Clonidinum; Clonidina; Clonidinum [INN-Latin]; Clonidinhydrochlorid; CATAPRES-TTS-3; CATAPRES-TTS-1; CATAPRES-TTS-2; N-(2,6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine; Isoglaucon; 2-(2,6-Dichloroanilino)-2-imidazoline; Dixarit; SKF 34427; Catapres- TTS; Clonidina [INN-Spanish]; M-5041T; Hemiton; CLORPRES; clonidine (amino form); Adesipress; Clofenil; Clopheline; Duraclont; Gemiton; Klofelin; Klofenil; M 5041T; Catapres (TN); Catarpres-TTS; ST-155BS; Tenso-Timelets; Catarpres-TTS (TN); Clonidine [USAN:BAN:INN]; Clonidine (JAN/USAN/INN); 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-(9CI); 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine; 2,6-dichloro-N-(2-imidazolidinylidene)aniline; 2,6-dichloro-N-2-imidazolidinylidenebenzenamide; 2,6-dichloro-N-imidazolidin-2-ylideneaniline; 2-((2,6-Dichlorophenyl)imino)imidazolidine; 2-(2,6-Dichloroanilino)-1,3-diazacyclopentene-(2);2-(2,6-Dichloroanilino)-2-imidazoline; 2-(2,6-Dichlorophenylamino)-2-imidazoline; 2-(2,6-Dichlorophenylimino)imidazolidine; 2-Imidazoline, 2-(2,6-dichloroanilino)-(7CI,8CI); 2-[(2,6-Dichlorophenyl)imino]imidazoline; 2-[(2,6-dichlorophenyl)imino]-2-imidazoline; 734571A; 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Diabetic neuropathy [ICD-11: 8C0Z] | Phase 3 | [3] | ||
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Intas Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H9Cl2N3
|
|||
| Canonical SMILES |
C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
|
|||
| InChI |
1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
|
|||
| InChIKey |
GJSURZIOUXUGAL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 4205-90-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
840960, 841959, 4807400, 5991864, 7847347, 7978974, 8151812, 10522369, 10527768, 11110984, 11110985, 11113648, 11120350, 11120838, 11121326, 11121653, 11122133, 11335949, 11361188, 11362722, 11364235, 11365284, 11366797, 11367846, 11369359, 11370715, 11370716, 11371375, 11373447, 11374710, 11376008, 11377521, 11462160, 11466276, 11467396, 11484969, 11485991, 11489003, 11490174, 11492771, 11495155, 14822899, 15172366, 26697416, 26697467, 26751841, 26751842, 29221958, 46508119, 47216577
|
|||
| ChEBI ID |
CHEBI:3757
|
|||
| ADReCS Drug ID | BADD_D00502 ; BADD_D00503 | |||
| SuperDrug ATC ID |
C02AC01; N02CX02; S01EA04
|
|||
| SuperDrug CAS ID |
cas=004205907
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-2 (ADRA2) | Target Info | Agonist | [4], [5], [6] |
| Membrane copper amine oxidase (AOC3) | Target Info | Inhibitor | [7] | |
| BioCyc | Phenylethylamine degradation I | |||
| Spermine and spermidine degradation I | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| beta-Alanine metabolism | ||||
| Metabolic pathways | ||||
| Panther Pathway | Phenylethylamine degradation | |||
| Pathwhiz Pathway | Beta-Alanine Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 516). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070315. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. | |||
| REF 5 | The alpha2 -adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens. 2001 Dec;19(12):2115-24. | |||
| REF 6 | Effects of intrathecal vs. systemic clonidine in treating chronic allodynia-like response in spinally injured rats. Brain Res. 1996 Oct 14;736(1-2):28-34. | |||
| REF 7 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.